The mammalian target of rapamycin (mTOR) is a serine/threonine kinase involved in nutrient sensing and cell growth and is a validated target for oncology and immunosuppression. Two modes of direct small-molecule inhibition of mTOR activity are known: targeting of the kinase active site and a unique mode in which the small molecule rapamycin, in complex with FKBP12 (the 12-kDa FK506 binding protein), binds to the FRB (FKBP12/rapamycin binding) domain of mTOR and inhibits kinase activity through a poorly defined mechanism. To facilitate the study of these processes, the authors have expressed and purified a truncated version of mTOR that contains the FRB and kinase domains and have developed homogeneous fluorescence-based assays to study mTOR activity. They demonstrate the utility of these assays in studies of active sitedirected and FRB domain-directed mTOR inhibition. The results suggest that these assays can replace traditional radiometric or Western blot-based assays. (Journal of Biomolecular Screening 2008:238-244) 
INTRODUCTION
T HE MAMMALIAN TARGET OF RAPAMYCIN (mTOR) is a large, multidomain protein and in cells functions as a complex with other accessory proteins. Two distinct complexes have been described: a rapamycin-sensitive complex (mTORC1) and a rapamycin-insensitive complex (mTORC2). In vivo, the mTORC1 complex promotes cell growth in response to nutrients through phosphorylation of p70S6K and 4E-BP1, which act to upregulate transcription through distinct mechanisms. The mTORC2 complex promotes cell growth and survival by a positive feedback mechanism, phosphorylating AKT at Ser 473 1 and serving as the elusive PDK2 by fully activating AKT in concert with PDK1, which phosphorylates AKT at Thr 308.
Elucidation of the biological functions of mTOR has been facilitated by the macrolide rapamycin, which shows exquisite specificity for mTOR due to its unique mode of action. Alone, rapamycin shows very low affinity (low-μM K d ) for mTOR and high affinity (low-nM K d ) for the abundant cellular protein FKBP12 (referred to as FKBP hereafter). FKBP alone also exhibits low affinity for mTOR, but the rapamycin⋅FKBP complex shows high affinity for mTOR. The binding site for the rapamycin⋅FKBP complex is in the FRB (FKBP-rapamycin binding) domain of mTOR that is separate from the domain containing the kinase active site. mTOR activity is inhibited by binding of the rapamycin⋅FKBP complex to the FRB domain, but the mechanism of this inhibition is poorly defined. Despite the poorly understood mechanism of inhibition, rapamycin is approved for use as an immunosuppressant and is used in drug-eluting stents to prevent restenosis following balloon angioplasty. A rapamycin analog, temsirolimus, has recently been approved for treatment of advanced kidney cancer, and other mTOR-targeting rapamycin analogs such as AP23573 and RAD-001 are in clinical trials for a variety of oncology indications.
To date, most reported biochemical studies of mTOR activity have been performed using mTOR that has been immunoprecipitated from mammalian cells, using a radiometric assay readout of phosphorylation of p70S6K or 4E-BP1. Recently, the expression and purification of recombinant mTOR expressed in HEK293 cells has been described, 2 but to date, there have been no reports of homogeneous fluorescence-based assays to measure mTOR activity. Herein we describe the characterization of a truncated mTOR construct that contains the FRB and kinase domains that was expressed in insect cells. We have developed homogeneous, fluorescence-based methods that are capable of measuring mTOR activity against either protein or peptide substrates or of measuring mTOR-catalyzed adenosine triphosphate (ATP) hydrolysis. In addition, we developed a non-activity-based binding assay designed to characterize rapamycin-like molecules that mediate interaction between the FRB domain and FKBP or that could be used to identify and characterize molecules that bind to the FRB domain in an FKBP-independent manner.
MATERIALS AND METHODS

General reagents
N-terminal GST-tagged mTOR (residues 1360-2549), GFP-4E-BP1, Tb-anti 4E-BP1 (pThr 46), NDP Sensor, staurosporine, and GFP-FKBP were from Invitrogen Corporation (Carlsbad, CA). Rapamycin, Wortmannin, PI-103, and LY294002 were from EMD Biosciences (Gibbstown, NJ). FKBP and FK506 were from Sigma-Aldrich (St. Louis, MO). Unlabeled 4E-BP1 was expressed and purified from Escherichia coli or purchased from Stratagene. Curve fitting and data analysis were performed with GraphPad Prism software (GraphPad Software, San Diego, CA).
Radiometric assay of mTOR activity using 4E-BP1 as substrate
Kinase reactions were performed at 30 °C in buffer containing 50 mM HEPES (pH 7.5), 0.01% polysorbate 20, 10 mM MnCl 2 , 1 mM EGTA, and 2.5 mM dithiothreitol (DTT) in a 25-μL assay volume. To 20-μL solutions containing buffer, substrate, and [ 32 P]-ATP was added 5.0 μL of 50 μg/mL mTOR in 20 mM HEPES, 0.1 mg/mL bovine serum albumin (BSA), 0.02% polysorbate 20, and 2 mM DTT. Assays were performed in duplicate. The final concentration of 4E-BP1 substrate in the reaction was 400 μg/mL, and the final concentration of mTOR was 10 μg/mL (61 nM). After 10 min, 20 μL of 1% BSA was added to the reaction, followed immediately by the addition of 1 mL cold 10% trichloroacetic acid (TCA) to stop the reaction. The stopped reactions were incubated on ice for at least 10 min before being applied to a nitrocellulose filter under vacuum, washed 3 times with cold 5% TCA, and counted on a scintillation counter.
TR-FRET-based assay for mTOR activity using GFP-4E-BP1 as substrate
Time-resolved fluorescence resonance energy transfer (TR-FRET) assays were performed in a manner similar to that described previously for other kinases 3 in 10-μL volumes in black, low-volume, 384-well plates from Corning (#3676, Corning, NY) using 150 ng/mL (0.9 nM) mTOR, 400 nM GFP-4E-BP1, and 10 μM ATP unless indicated otherwise. Assay buffer consisted of 50 mM HEPES (pH 7.5), 0.01% polysorbate 20, 1 mM EGTA, 10 mM MnCl 2 , and 1% DMSO. After a 1-h room temperature reaction, the assay was stopped by addition of 10 μL of 20 mM EDTA and 4 nM Tb-anti-pThr 46 4E-BP1 antibody in TR-FRET dilution buffer (Invitrogen). After a 1-h incubation at room temperature, TR-FRET measurements were obtained on either a Tecan Ultra™ or BMG Pherastar™ plate reader. All assays were performed using either 3 or 4 replicate wells for each data point represented. For comparative purposes between formats and assays, the TR-FRET ratios were normalized relative to a sample containing no inhibitor. Samples that were preincubated with wortmannin for 1 h prior to addition of ATP and substrate were normalized relative to samples that underwent no preincubation.
FRET-based assay for mTOR activity against octapeptide substrate
FRET-based assays were performed in a manner similar to that described previously for other kinases 4 in 10-μL volumes in black, low-volume, 384-well plates from Corning (#3676) using 4 μg/mL (24 nM) mTOR, 2 μM Z′-LYTE™ Ser/Thr11 peptide substrate (Invitrogen), and 10 μM ATP. Assay buffer consisted of 50 mM HEPES (pH 7.5), 0.01% BRIJ-35, 1 mM EGTA, 5 mM MnCl 2 , 5 mM MgCl 2 , 1 mM DTT, and 1% DMSO. After a 1-h room temperature reaction, the assay was stopped by addition of 5 μL of development reagent, and after an additional 1-h incubation, fluorescence measurements were obtained on a Tecan Safire™ plate reader. The extent of substrate phosphorylation was calculated from the FRET ratio as described previously. 4 All assays were performed using 3 replicate wells for each data point represented.
NDP assay for mTOR-catalyzed ATP hydrolysis
ATP hydrolysis assays were performed with the NDP Sensor, a coumarin-labeled form of nucleoside diphosphate kinase that responds to changes in ATP/adenosine diphosphate (ADP) ratios. 5 To increase precision of the NDP Sensor assay, a PyMPO-Tris conjugate was added to the reactions as a reference fluorophore. The PyMPO conjugate was prepared by adding 50 μL of 10 mg/mL PyMPO-SE (Invitrogen) to 500 μL of 100 mM Tris (pH 8.3), followed by incubation at room temperature for approximately 16 h. Adenosine triphosphatase (ATPase) reactions were performed in 12-μL volumes in black, low-volume, 384-well plates from Corning (#3676) using 7.5 μg/mL (46 nM) mTOR and 16 μM ATP in buffer consisting of 50 mM HEPES (pH 7.5), 0.01% polysorbate 20, 1 mM EGTA, 10 mM MnCl 2 , and 1% DMSO. After a 1-h room temperature reaction, 8 μL of a detection mix was added consisting of 167 nM NDP Sensor and 333 nM PyMPO conjugate. After 10 min, fluorescence measurements were obtained on a BMG Pherastar™ plate reader with excitation at 420 nm and emission at 480 and 600 nM for NDP Sensor and PyMPO reference, respectively. Emission values were taken as the ratio of NDP Sensor emission (420 nm) to PyMPO emission (580 nm).
Assay for rapamycin-mediated association of mTOR with GFP-FKBP
A pRSETa (Invitrogen) expression plasmid was constructed that encoded EmGFP-FKBP (linked by 3 Gly residues) and an N-terminal HIS tag and was expressed in E. coli BL21*DE3 cells. The resulting protein was purified by standard Ni-NTA chromatography and dialyzed into HEPES-buffered saline (HBS, pH 7.5) prior to use in the binding assay. Binding assays were performed by first preparing a solution containing 4 nM GSTtagged mTOR, 2 nM Tb-anti-GST (Invitrogen), and 50 nM GFP-FKBP in the presence or absence of 10 μM FK-506 in TR-FRET dilution buffer. This solution was allowed to equilibrate 10 min at room temperature before 10-μL aliquots were added to a 10-μL dilution series of rapamycin (thereby diluting the initial concentrations of reagents by 2-fold). The binding assay was allowed to equilibrate for 1 h at room temperature before TR-FRET measurements were made.
RESULTS AND DISCUSSION
Characterization of recombinant mTOR FRB-kinase domain expressed from insect cells
The FRB-kinase domain construct used was based on the previously described construct of Toral-Barza and colleagues, 2 which was based on previous work that showed that the sequence required for mTOR activity in vitro included the kinase domain, the FRB domain, and a substantial additional C-terminal sequence. 6 To facilitate both ease of protein production as well as purification, we expressed this construct as a GST (rather than FLAG-tag) fusion in insect (rather than HEK293) cells. Purification by glutathione-sepharose followed by anion exchange yielded a protein that migrated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel at an apparent molecular weight of slightly less than a 160-kDa marker (using BenchMark™ protein ladder), consistent with the calculated molecular weight of 164 kDa. The identity of the purified protein was further confirmed by mass spectrometry analysis. A contaminating band at approximately 75 kDa was also identified by tandem mass spectrometry (MS/MS) as the chaperone protein HSP70 (see Fig. 1 ). In a radiometric assay using His-tagged 4E-BP1 as the substrate, an ATP K m of 19 μM was determined, which is in line with the 50-μM value reported previously for the FLAGtagged construct. 2 K m,app values of 8 μM and 11 μM were determined in the TR-FRET and FRET-based assays, respectively (data not shown). These K m values are substantially different from a 1-mM value that was initially reported using immunoprecipitated mTOR. 7 Although we do not have an explanation for the discrepancy with this initially reported value, we are unaware of other reports suggesting this high an ATP K m value for mTOR. Specific activity of the kinase was 14 nmole phosphate transferred/(min⋅mg).
Characterization of mTOR (1360-2549) inhibition with ATP site-directed inhibitors
To validate the homogeneous fluorescence assays, we performed assays using LY249002 and PI-103, which are welldescribed, reversible ATP competitors of mTOR, wortmannin (a time-dependant, covalent inhibitor of mTOR), and staurosporine, which has been reported to lack activity against mTOR. 8, 9 Similar results were obtained in either the TR-FRET assay format using GFP-4E-BP1 as substrate or in the FRET-based format using the octapeptide substrate ( Fig. 2 and Table 1 ) and were consistent with previously reported potencies. Reproducibility of inhibitor IC 50 values was within 2-fold for experiments performed on separate days, and Z′ values were 0.90 and 0.81 for the TR-FRET and FRET-based formats, respectively (data not shown). Staurosporine showed virtually no effect on kinase activity, whereas LY249002 inhibited with low-μM potency in either format. Wortmannin inhibited in a time-dependant manner, with an IC 50 value that decreased between 2-and 5-fold upon preincubation of the compound with kinase prior to the assay. PI-103 inhibited with an approximately 40-to 50-nM IC 50 , which is consistent with reported values of 20 and 83 nM against the mTORC1 and mTORC2 complexes, respectively. 8 In the course of the preincubation experiments with wortmannin, we observed an approximately 35% decrease in kinase activity of the diluted kinase over a 1-h timeframe. This reduction in activity could be reduced slightly by the addition of DTT to a concentration of 2 mM, with no impact on IC 50 values (data not shown). Although the FRB domain has been shown to destabilize proteins to which it is fused, 10 we observed no decrease in the activity of concentrated mTOR stocks (stored at 450 μg/mL in 50 mM Tris [pH 7.5], 150 mM NaCl, 0.5 mM EDTA, 0.1% Tween-20, 2 mM DTT, 50% glycerol) when stored at -20 °C or -80 °C for 4 weeks, no decrease in activity after 5 freeze-thaw cycles, and only a 12% decrease when stored at room temperature for 4 h (data not shown). However, our assay results and the fact that the construct copurifies with the chaperone protein HSP70 suggest an inherent lack of stability of the purified truncated construct.
Characterization of mTOR (1360-2549) inhibition with rapamycin
Inhibition of mTOR (1360-2549) with rapamycin in the presence and absence of FKBP is shown in Figure 2 and Table 1 . In both fluorescent assay formats, the extent of inhibition by rapamycin in the presence of FKBP reached a plateau, with substantial activity remaining under saturating amounts of rapamycin. A similar plateau showing approximately 55% remaining activity was confirmed in a radiometric assay using His-tagged 4E-BP1 as the substrate (data not shown). The IC 50 value in the TR-FRET format, 1.8 nM, is identical to that previously reported for recombinant mTOR expressed from mammalian cells, 2 whereas the assay using the octapeptide substrate is right-shifted to 30 nM, which is consistent with the higher concentration of enzyme required in the FRET-based format using this substrate (24 vs. 0.9 nM required in the TR-FRET-based format using GFP-4E-BP1 as the substrate). When the experiment was repeated in the TR-FRET format using 100 μM ATP, there was no shift in the potency of rapamycin in the presence of FKBP, consistent with the non-ATP competitive nature of this inhibition (data not shown). In addition, in both assay formats, there was a slight but reproducible decrease in activity in the presence of rapamycin alone above 1 μM, but we were unable to demonstrate a clear plateau due to solubility issues with rapamycin beyond 100 μM.
After demonstrating the ability of rapamycin to inhibit mTOR activity against either protein or peptide substrates, we characterized the effects of rapamycin on mTOR-catalyzed, substrateindependent ATP hydrolysis in the presence or absence of FKBP (see Fig. 3 ). Although the ATP site-directed inhibitors wortmannin and PI-103 inhibited ATP hydrolysis with IC 50 values comparable to those observed in the activity assays against a peptide or protein substrate (see Table 1 ), rapamycin showed no effect on the reaction in either the presence or absence of FKBP.
The incomplete inhibition against 4E-BP1 that was observed in the activity assays is in agreement with a previous report that rapamycin⋅FKBP inhibits mTOR activity against some, but not all, phosphorylation sites in 4E-BP1. 11 The lack of complete inhibition of mTOR kinase activity against 4E-BP1 by rapamycin⋅FKBP is in contrast to reports using p70S6K as a substrate, in which inhibition has been shown to be complete. 2, 10, 11 Although one could reconcile these results by invoking a model in which recruitment of a bulky FKBP protein proximal to the kinase active site differentially occludes access to substrate phosphorylation site(s), it seems less likely (but possible) that such an effect would be seen when using the smaller octapeptide substrate in the FRET-based assay. However, our results showing that rapamycin⋅FKBP had no effect on the rate of mTOR-catalyzed ATP hydrolysis would be consistent with a steric occlusion model of inhibition, in which recruited FKBP does not block access by the small ATP moiety.
Rapamycin is a member of a class of immunosuppressant compounds that includes FK506 and cyclosporine A (CsA).
These compounds function through a unique mechanism in which the compound itself first must bind to an abundant cellular protein referred to as an immunophilin (FKBP for rapamycin and FK506, or cyclophilin A for CsA) to form a complex that then, through interactions of the composite surface formed by the small molecule and the immunophilin, binds tightly to a second target protein (the serine/threonine phosphatase calcineurin for the CsA⋅cyclophilin A and FK506⋅FKBP complexes 12 and mTOR for the rapamycin⋅FKBP complex 13, 14 ) to exert their biological effects. Moreover, in all these examples, the drug⋅immunophilin complex binds to a region of calcineurin or mTOR that is distinct from the active site. Although a crystal structure of a construct containing both the FRB and catalytic domains of mTOR either free or in complex with rapamycin⋅FKBP has yet to be determined, there is evidence that binding of small molecules (including rapamycin) to the FRB domain can modulate mTOR activity in the absence of FKBP 2, 15 and that mutations in the FRB domain can either increase or decrease catalytic activity of mTOR in a substrate-dependant manner. 11 Thus, there appears to be some regulatory effect of the FRB domain on the mTOR catalytic domain that is independent of the presence of rapamycin⋅FKBP and that can be modulated by small molecules in the absence of chaperone proteins such as FKBP.
Direct measure of rapamycin-mediated association of mTOR with FKBP
To directly measure the rapamycin-mediated association of mTOR with FKBP, we incubated the GST-tagged mTOR construct with GFP-tagged FKBP in the presence of Tb-labeled anti-GST tag antibody, and TR-FRET was measured between the Tb label and GFP as rapamycin was added to the solution (see Fig.  4 ). A robust change in the TR-FRET ratio was observed, with an EC 50 value of 1.4 nM, consistent with the IC 50 values determined in the activity assays as well as the previously reported low nM values observed in traditional "pull-down" binding assays 16 or biochemical assays using the isolated FRB domain. 17 A Z′ value between fully associated and nonassociated complex was determined to be 0.83. The rapamycin-mediated association was substantially reduced in the presence of excess FK506, which competes with rapamycin for binding to the same binding pocket in FKBP.
Implications for the identification and characterization of FRB-binding molecules
Very recently, studies toward the development of smallmolecule mTOR inhibitors that do not recruit FKBP and that target the rapamycin⋅FKBP binding site in the FRB domain have been described. 15 Although a small molecule that is structurally dissimilar from rapamycin and that weakly inhibited mTOR activity at high concentrations was identified, rapamycin itself (in the absence of FKBP) showed a larger effect, with an IC 50 of approximately 3 μM. This value is comparable to the K d that has been determined for the interaction of rapamycin⋅FKBP with isolated FRB 17 and is in line with our data and others 2 showing that rapamycin alone weakly inhibits mTOR activity at μM concentrations. These results, coupled with other data showing that mutations in the FRB domain can affect activity in the kinase domain, 11 suggest that the FRB domain does have a modulatory effect on the kinase domain and that small-molecule targeting of the FRB domain may be a strategy toward selective mTOR inhibitors. Although small molecules can be identified in an activity-based assay, the simplicity and dynamic range of the associative assay that we have described using a GFP fusion of FKBP as a FRET acceptor for a Tb-labeled anti-GST-tagged antibody that binds to the GST-tagged mTOR should facilitate the identification of such molecules. These molecules would disrupt the rapamycin-mediated interaction of mTOR with rapamycin⋅FKBP-GFP in a manner analogous to the disruption by FK506 that we have shown. In either the activity-based TR-FRET assay or the association-based assay, approximately 10% inhibition (of either activity or association) is required to fall outside 3 standard deviations of the appropriate control wells. Because of the smaller assay window for rapamycin-mediated inhibition in the activity assay (approximately 45% of activity is inhibited at saturating concentrations of rapamycin⋅FKBP), the association-based assay would be expected to be more robust for identifying less potent rapamycin-like molecules in an highthroughput screening format. In addition, the binding assay should provide a simple method for the characterization of binding affinities of rapamycin analogs.
CONCLUSIONS
Targeting of mTOR by rapamycin or rapamycin analogs has led to approved drugs for such diverse indications as preventing graft rejection following transplantation, preventing restenosis following balloon angioplasty, and treating kidney cancer. Despite the massive efforts required to develop rapamycin for these purposes, the precise details of the mechanism(s) of inhibition of mTOR kinase activity by rapamycin are far from clear. The regulation of mTOR activity in vivo is likely to be far more complex than can be adequately re-created using recombinant complexes, and techniques that isolate and then assay specific mTOR complexes from cells will remain critical to the further elucidation of mTOR regulation. The TR-FRET assay system that we have described has been successfully applied to the assay of such complexes (Nathanael Gray, Dana Farber Cancer Institute, personal communication) and should therefore be useful toward further studies designed to more clearly elucidate the regulation and function of this fascinating and enigmatic kinase. 
